MYCN and neuroblastoma: Anti-tumour activity is evident in preclinical models of acute T-cell leukaemia [18], multiple myeloma [19], MYCN-amplified neuroblastoma [20], small cell lung cancer [21], triple-negative breast cancer [22] and colorectal cancer [23].